Junshi Biosciences’ Neotorch is the world’s first registered Phase III immuno-oncology trial for lung cancer to post positive EFS (event-free survival) data.
Seattle-based Alpine Immune Sciences voluntarily terminated enrollment in two clinical trials of its immuno-oncology asset, davoceticept, after a second patient death. The company now plans to focus its attention on ALPN-303 for autoantibody-related inflammatory diseases.
A separation of Sandoz via a 100 percent spin-off will create the leading European generics company and a global leader in biosimilars, and a more focused Novartis.
Elevation Oncology, Janssen, Merck and Teclison discuss the latest innovations in immuno-oncology.
Roche acquired privately held Good Therapeutics and its immuno-oncology platforms for $250 million, plus future milestone payments, on Wednesday.
Clinical-stage biopharma company Mersana Therapeutics unveiled a global collaboration with GlaxoSmithKline Monday that gives the industry behemoth the exclusive option to co-develop and commercialize Mersana’s antibody-drug conjugate (ADC) XMT-2056.
MiroBio and Gilead believe they can offer new, best-in-class assets to patients beset by different autoimmune diseases. The deal includes MiroBio’s lead investigational candidate, MB272, a selective agonist of T, B and dendritic cells that aims to inhibit or blunt activation and suppress an inflammatory immune response.
Marengo Therapeutics and Ipsen announced Monday that they have entered into a strategic, multi-year partnership to usher two of Marengo’s precision T cell immuno-oncology candidates into the clinic.